1. Home
  2. WEYS vs CABA Comparison

WEYS vs CABA Comparison

Compare WEYS & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Weyco Group Inc.

WEYS

Weyco Group Inc.

HOLD

Current Price

$31.86

Market Cap

280.9M

ML Signal

HOLD

Logo Cabaletta Bio Inc.

CABA

Cabaletta Bio Inc.

HOLD

Current Price

$3.36

Market Cap

319.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WEYS
CABA
Founded
1906
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Apparel
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
280.9M
319.6M
IPO Year
1995
2019

Fundamental Metrics

Financial Performance
Metric
WEYS
CABA
Price
$31.86
$3.36
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$14.57
AVG Volume (30 Days)
4.7K
2.8M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
3.33%
N/A
EPS Growth
N/A
N/A
EPS
1.50
N/A
Revenue
$290,290,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$21.99
N/A
Revenue Growth
N/A
N/A
52 Week Low
$25.51
$0.99
52 Week High
$34.63
$3.78

Technical Indicators

Market Signals
Indicator
WEYS
CABA
Relative Strength Index (RSI) 56.42 63.08
Support Level $31.06 $2.11
Resistance Level $33.40 $3.73
Average True Range (ATR) 0.81 0.30
MACD 0.04 0.02
Stochastic Oscillator 74.19 67.11

Price Performance

Historical Comparison
WEYS
CABA

About WEYS Weyco Group Inc.

Weyco Group Inc is a company, engaged in the manufacturing, designing, and distribution of footwear. The company designs and markets footwear for men, women, and children. It markets its apparel, accessories, and footwear under the brand names of Florsheim, Nunn Bush, Stacy Adams, BOGS, Rafters, and Forsake. The company organizes its business into two segments; the North American wholesale operations and the North American retail operations. The majority of the company's revenue is generated from the wholesale segment under which its products are sold to footwear, department, and specialty stores, as well as e-commerce retailers. The company has operational footprints in the United States which generates key revenue, Canada, Asia, South Africa, and Australia.

About CABA Cabaletta Bio Inc.

Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.

Share on Social Networks: